Given decitabine (DAC), a clinically approved DNMT inhibitor, has shown promising efficacy and clinical safety in phase I clinical trials for melanoma,[16, 19] DAC was selected to combine with ICAM1‐ADCs to explore the potential synergistic antitumor efficacy in vitro and in vivo. Here, ICAM1 is linked to melanoma.